A study found that women with specific genomic alterations in circulating tumor DNA had worse survival outcomes in metastatic breast cancer. The detection of TP53 and ESR1 alterations was linked to poorer survival, while PIK3CA alterations showed no association. The study suggests that circulating tumor DNA could be a prognostic biomarker in this setting, guiding future therapeutic decisions. Liquid biopsy with ctDNA detection is minimally invasive and provides better insight into tumors compared to tissue biopsies. Despite study limitations, the findings may influence the design of future clinical trials and benefit patients with metastatic breast cancer.
Source link
Detection of specific alterations in ctDNA prognostic in metastatic breast cancer
